Recorded device evidence

AltaTrack Equipment R1.2, AltaTrack Guidewire, AltaTrack 3D Hub (K223918): indications, design and recorded evidence

The acquired K223918 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 91 selected decisions under primary code DQK. 91 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 68.5, median 113.0, upper quartile 172.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K223918 ↗ · this pageAltaTrack Equipment R1.2, AltaTrack Guidewire, AltaTrack 3D Hub2022-12-29 → 2023-06-08161Abbreviated
K261729 ↗EnSite™ X EP System2026-05-26 → 2026-09-17114Traditional
K262005 ↗Affera Integrated Mapping System2026-06-15 → 2026-08-2167Special
K253692 ↗AVVIGO™+ Multi-Modality Guidance System2025-11-21 → 2026-08-21273Traditional
K253576 ↗CorVista System® with PCWP Add-On2025-11-17 → 2026-07-26251Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K223918 · PDF page 3 ↗ Source 2

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K223918 · PDF page 5 ↗ Source 3

The AltaTrack system consists of the following primary devices:

                                               The AltaTrack Equipment R1.2 is a visualization device with Fiber Optic
                                               RealShape (FORS) technology.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K223918 · PDF page 6 ↗ Source 4

Note that the AltaTrack Catheter is no longer supported by AltaTrack
                               Equipment R1.2 and that the AltaTrack Guidewire, remaining the same, did
                               not require any non-clinical performance testing.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Historical references beside dated FDA recognition metadata

Read each mention in the linked original summary, including statements that testing was not performed. Recognition metadata does not determine your testing needs, chosen edition or transition eligibility.

Reference in this historical summaryDesignation in the acquired FDA exportRecognition / entry dateRecorded transition-expiration dateSources
ISO 14971:2019
Performance Data
ISO 14971 Third Edition 2019-12
Medical devices - Application of risk management to medical devices
5-125 · Complete
12/23/2019
Not recorded in this export rowSummary [4] · Metadata [5]
Read scope and recognition limits ↗
ISO 14971:2019
Performance Data
ANSI AAMI ISO 14971: 2019
Medical devices - Applications of risk management to medical devices
5-125 · Complete
12/23/2019
Not recorded in this export rowSummary [4] · Metadata [6]
Read scope and recognition limits ↗
ISO 15223-1:2021
Performance Data
ISO 15223-1 Fourth edition 2021-07 [Including AMD1: 2025]
Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements [Including Amendment 1 (2025)]
5-148 · Complete
12/22/2025
Not recorded in this export rowSummary [4] · Metadata [7]
Read scope and recognition limits ↗
ISO 15223-1:2021
Performance Data
ISO 15223-1 Fourth edition 2021-07
Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements
5-134 · Complete
12/20/2021
12/17/2028Summary [4] · Metadata [8]
Read scope and recognition limits ↗
ISO 20417
Performance Data
ISO 20417 Second edition 2026-03
Medical devices - Information to be supplied by the manufacturer
5-149 · Complete
05/25/2026
Not recorded in this export rowSummary [4] · Metadata [9]
Read scope and recognition limits ↗
ISO 20417
Performance Data
ISO 20417 First edition 2021-04 Corrected version 2021-12
Medical devices - Information to be supplied by the manufacturer
5-135 · Complete
12/19/2022
07/01/2029Summary [4] · Metadata [10]
Read scope and recognition limits ↗

Prepare for your provider: the proposed protocol/report edition, its justification for your device and the complete current FDA recognition sheet. In particular, inspect exclusions for partial recognition. An edition difference does not automatically make the historical evidence unusable.

Identifier-matching method and selection limits

Match explicit ISO/IEC identifiers in selected preserved summary excerpts to the acquired, count-reconciled FDA metadata export. Preserve the historical edition mention, current snapshot designations, entry dates, recognition extent and any recorded transition-expiration date as separate facts. No title-similarity, edition-equivalence, test-mandate or transition-eligibility inference. At most twenty matched occurrences and thirty metadata rows per reference; wide matches are held for separate review.

3 of 3 matched reference occurrences shown.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK223918 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryAltaTrack Equipment R1.2, AltaTrack Guidewire, AltaTrack 3D Hub [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantPhilips Medical Systems Nederland B.V. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeDQK [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2023-06-08 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeAbbreviated [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2022-12-29 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

  4. Which edition and recognition limits would our provider rely on?

    Compare each historical reference below with the dated FDA metadata. Ask the specialist to justify the applicable scope and selected edition, read the complete supplementary sheet for partial-recognition exclusions, and investigate any recorded transition conditions. A difference in editions does not automatically make the earlier study unusable.

    Useful evidence: Proposed protocol/report edition, dated FDA recognition sheet with scope/exclusions, and a documented edition/transition rationale for the actual device.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[113506] · record b05657900c11f2512603471afb090378a701e83407b5ea0b0c35ea86c4c211cd
  • [11] Complete results array / fda-decision-context:K223918 · record whole dataset partition

FDA 510(k) summary — K223918 ↗

Tue, 20 Jun 2023 17:24:02 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 523d5603e0ca2962729d561a2b5758828b4746d0b71d829156a3a18d39c8b0d8

  • [2] PDF page 3 · record 9436c088f087e5597a46476744aa5fb57c25de996bafa5393b6ccfb4f874b5be
  • [3] PDF page 5 · record beee9d0007c869a5d1d7fb9275b9c421e5ad355dfb62a2afc3bfcd05dfa204fe
  • [4] PDF page 6 · record bb3b066bcd6f542e0fbe3c07d963f7db5da54b713578a792841a16f2fd8cf0d6

FDA — recognition metadata exported through the official search form ↗

Version not stated by the source · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 94ccf56dc846c7f6d78d6ad77dc6e87d1803ac3612af01d6894949e34c4a78d8

  • [5] CSV row 1011 · record 80abd02faa312db476deb65293af52c610c8ebeac4c377520dd2764555642427
  • [6] CSV row 1012 · record 0425f4fc51db72ca07c5e98184058381b2bb3ee51a538f41f108c706b7a077ec
  • [7] CSV row 119 · record 4807867f84651019bfe4bf51c9e3ae597bf279825c2b2415648a2657e3903e82
  • [8] CSV row 709 · record 71e42ed9514a35b292e75a119b9fbf800bdf89917ca23000383092ab3ac90bc3
  • [9] CSV row 51 · record 8b417e152b0e453471cd0d1f092542bbee98eff179a865d34c8339c1079279fb
  • [10] CSV row 598 · record 58c57193ef82d921b5628db44f52f7f34e704c199212b40c0d51172d6c75ab79

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services